Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERCC1-Tailored Chemotherapy in NSCLC
NCT00174629Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2001
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoint: Overall Response Rate. Started Jun 2001; status: completed.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00174629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174629.